The Role of Everolimus in Renal Cell Carcinoma

Malek Meskawi, Roger Valdivieso, Paolo Dell’Oglio, Vincent Trudeau, Alessandro Larcher, Pierre I Karakiewicz

Abstract


Everolimus (RAD001) is an orally administered agent that inhibits the mammalian target of rapamycin serine-threonine kinase. A phase III pivotal trial on everolimus, published in 2008, provided the first evidence for the efficacy of sequential therapy for patients with metastatic clear cell renal cell carcinoma (RCC). In this study, everolimus was used after failure of one or several previous lines of therapy, and it demonstrated a 3-month survival benefit relative to placebo. Currently, based on the level 1 evidence, everolimus represents the molecule of choice for third-line therapy after failure of previous two tyrosine kinase inhibitors (TKIs). However, second-line use after failure of one TKI is challenged by two new molecules (nivolumab and cabozantinib), which proved to have better efficacy with similar toxicity profile. In non-clear cell metastatic RCC, the current evidence recommends everolimus as a second-line therapy after failure of previous first-line sunitinib.


Keywords


Everolimus; kidney cancer; renal cell carcinoma

Full Text:

HTML PDF


DOI: http://dx.doi.org/10.15586/jkcvhl.2015.43

Article Metrics

Metrics Loading ...




Copyright (c) 2015 Malek Meskawi, Roger Valdivieso, Paolo Dell’Oglio, Vincent Trudeau, Alessandro Larcher, Pierre I Karakiewicz

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.